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Background: Myelosuppressive chemotherapy can lead to dose-limiting febrile neutropenia. Prophylactic use of
recombinant human G-CSF such as daily filgrastim and once-per-cycle pegfilgrastim may reduce the incidence
of febrile neutropenia. This comparative study examined the effect of pegfilgrastim versus daily filgrastim on the
risk of hospitalization.
Methods: This retrospective United States claims analysis utilized 2004–2009 data for filgrastim- and
pegfilgrastim-treated patients receiving chemotherapy for non-Hodgkin’s lymphoma (NHL) or breast, lung,
ovarian, or colorectal cancers. Cycles in which pegfilgrastim or filgrastim was administered within 5 days from
initiation of chemotherapy (considered to represent prophylaxis) were pooled for analysis. Neutropenia-related
hospitalization and other healthcare encounters were defined with a “narrow” criterion for claims with an ICD-9
code for neutropenia and with a “broad” criterion for claims with an ICD-9 code for neutropenia, fever, or
infection. Odds ratios (OR) for hospitalization and 95% confidence intervals (CI) were estimated by generalized
estimating equation (GEE) models and adjusted for patient, tumor, and treatment characteristics. Per-cycle
healthcare utilization and costs were examined for cycles with pegfilgrastim or filgrastim prophylaxis.
Results: We identified 3,535 patients receiving G-CSF prophylaxis, representing 12,056 chemotherapy cycles
(11,683 pegfilgrastim, 373 filgrastim). The mean duration of filgrastim prophylaxis in the sample was 4.8 days.
The mean duration of pegfilgrastim prophylaxis in the sample was 1.0 day, consistent with the recommended
dosage of pegfilgrastim - a single injection once per chemotherapy cycle. Cycles with prophylactic pegfilgrastim
were associated with a decreased risk of neutropenia-related hospitalization (narrow definition: OR = 0.43, 95%
CI: 0.16–1.13; broad definition: OR = 0.38, 95% CI: 0.24–0.59) and all-cause hospitalization (OR = 0.50, 95% CI:
0.35–0.72) versus cycles with prophylactic filgrastim. For neutropenia-related utilization by setting of care, there
were more ambulatory visits and hospitalizations per cycle associated with filgrastim prophylaxis than with
pegfilgrastim prophylaxis. Mean per-cycle neutropenia-related costs were also higher with prophylactic filgrastim
than with prophylactic pegfilgrastim.
Conclusions: In this comparative effectiveness study, pegfilgrastim prophylaxis was associated with a reduced
risk of neutropenia-related or all-cause hospitalization relative to filgrastim prophylaxis.* Correspondence: ANaeim@mednet.ucla.edu
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Patients receiving myelosuppressive chemotherapy are at
risk of developing febrile neutropenia, a major dose-
limiting toxicity of systemic chemotherapy associated
with hospitalization, use of intravenous antibiotics, and
significant morbidity, mortality, and costs [1-10]. Re-
combinant human granulocyte colony-stimulating factor
(G-CSF; filgrastim and pegfilgrastim) is indicated to reduce
the incidence of infection in patients with non-myeloid
malignancies receiving myelosuppressive chemotherapy
[2,4,5]. Guidelines recommend the prophylactic use of
G-CSF in patients receiving chemotherapy regimens that
have a 20% or greater risk of febrile neutropenia [11,12].
In addition, patients receiving chemotherapy regimens
associated with a febrile neutropenia risk below 20%
may have a total combined risk above 20% if they have
additional risk factors, such as comorbid conditions or
advanced age. Thus, these patients may benefit from
prophylactic G-CSF use as well [11-13].
Filgrastim is recommended to be administered at a
recommended starting dose of 5 mcg/kg per day
until neutrophil recovery occurs after the expected
chemotherapy-induced nadir. Its short circulating
half-life (~3.5 hours) necessitates that it be given
daily. The efficacy of filgrastim depends on the num-
ber of days it is administered. Randomized compara-
tive clinical trials have shown that patients treated
with a mean of 10–11 filgrastim doses per chemo-
therapy cycle reported a similar decrease in the dur-
ation of severe neutropenia as patients treated with
pegfilgrastim once per chemotherapy cycle [14-18].
In clinical practice, filgrastim is often administered for
fewer than 10–11 days and may be associated with
reduced efficacy [19]. A chart review study found that
the risk of hospitalization was approximately one-third
higher with filgrastim use compared to pegfilgrastim
use [20]. An additional retrospective observational
study of United States claims databases showed that
prophylactic use of pegfilgrastim was associated with a
one-third to two-thirds reduction in the risk of
hospitalization for febrile neutropenia relative to the
risk in patients who received filgrastim prophylaxis
[21]. Two more recent studies on comparative effect-
iveness of G-CSF prophylaxis reported similar findings
based on United States claims data [22,23].
Neutropenic complications following chemotherapy
contribute significantly to the costs of cancer care.
During 1989–2007, the number of neutropenia-related
hospitalizations among cancer patients in the United
States was estimated to be approximately 57,000–
103,000 per year [10]. In a study using 1995–2000 data,
the average cost per hospitalization due to febrile neu-
tropenia was reported to be $12,372 for breast cancer
patients, $18,437 for lymphoma patients, and $38,583for leukemia patients [3]. Another study using 2005–
2008 data found that mean hospitalization costs were
$18,042 for cancer patients with neutropenia, $22,839
for those with neutropenia plus infection or fever, and
$27,587 for those with neutropenia plus infection [9].
Clearly, neutropenic complications in patients receiv-
ing chemotherapy pose a significant medical and finan-
cial burden.
The primary objective of the current study was to
determine whether a difference in the risk of neutropenia-
related and all-cause hospitalization between chemother-
apy cycles associated with filgrastim prophylaxis and
cycles with pegfilgrastim prophylaxis. This study from a
United States claims database included data from January
2004 through February 2009 regarding filgrastim and peg-
filgrastim administration patterns and related clinical out-
comes. Additionally, economic data in the form of




This study was a retrospective United States claims ana-
lysis using data from health plans affiliated with Optu-
mInsight (formally Ingenix). This national database
contains both medical and pharmacy claims with linked
enrollment information data beginning in 1993. As of
2008, medical and pharmacy benefit coverage informa-
tion was available for over 14 million individuals.
All patient-identifying information was either encrypted
or removed from the study database prior to its release to
the study investigators. The study database does not
contain any Protected Health Information and is fully
compliant with the Health Insurance Portability and Ac-
countability Act (HIPAA) of 1996 and federal guidance
on Public Welfare and the Protection of Human Sub-
jects [24,25]. As per the Code of Federal Regulations,
Institutional Review Board review and approval is not
needed for a study of this nature, as “. . .subjects cannot
be identified, directly or through identifiers linked to the
subjects. . .” (45 CFR 46 §46.101). Use of this fully de-
identified and HIPAA-compliant study database for health
services research is therefore in full compliance with the
Helsinki Declaration [26].
Outcomes, including administration patterns, neu-
tropenia-related and all-cause hospitalization rates, and
utilization and cost data, were obtained for both filgrastim-
and pegfilgrastim-treated patients receiving chemotherapy
for non-Hodgkin’s lymphoma (NHL), breast cancer, lung
cancer, ovarian cancer, or colorectal cancer.
Patients with chemotherapy medical claims between
January 1, 2005 and February 28, 2009 were studied. The
year prior to the index date was used to determine
whether patients met inclusion/exclusion criteria and to
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date of the first chemotherapy claim of an eligible patient
was deemed the index date. Patients were included if they
had two or more medical claims ( ≥ 7 days apart) with
ICD-9 code(s) for NHL, breast cancer, lung cancer, ovarian
cancer, or colorectal cancer from 30 days prior to the index
date up to 30 days after the index date, and one or more
claim for filgrastim or pegfilgrastim (not both) during the
chemotherapy course. Claims from laboratories, diagnostic
testing centers, or any diagnostic tests were not considered
when identifying cancer patients, as well as claims with
“rule-out” codes (CPT-4 codes 36400–36425, 70010–
76999, 7800–78799, 80000–89999; HCPCS codes S9529,
G0001). Patients were excluded if they had less than 1 year
of continuous eligibility preceding the index date; any
claim for chemotherapy during the 1 year prior to the
index date; one or more medical claims for bone marrow
or stem cell transplant; claims indicating sargramostim use;
claims for services provided in skilled nursing facility or
hospice services; or if they had codes for more than one
type of primary cancer. Patients with metastatic disease
were not specifically excluded.
Besides tumor type and use of pegfilgrastim/filgrastim,
data collected also included demographic characteristics,
comorbid conditions, cancer treatment history, and
chemotherapy agents received in each chemotherapy
cycle. The first eligible chemotherapy course for each
patient after January 1, 2005 was used in this analysis.
Each chemotherapy course may include several cycles.
The first chemotherapy course began on the index date
and ended with any of the following, whichever came
first: 1) the absence of any chemotherapy claims within
the 60 days after a chemotherapy claim (ie, chemother-
apy gap); 2) the end of insurance eligibility or study
period; or 3) the initiation of radiation therapy. Chemo-
therapy cycles in the course were defined to identify
unique cycles of interest, and were excluded if two
chemotherapy claims had less than 20 days between
them or if there were chemotherapy claims from days
7–19 of a cycle [21]. Chemotherapy cycle length was
restricted to ensure a more homogeneous treatment
population consistent with the labeled indications of
both filgrastim and pegfilgrastim, as pegfilgrastim is not
indicated to support weekly or every-two-week chemo-
therapy cycles.
For both filgrastim and pegfilgrastim, use was categor-
ized as prophylactic (ie, initiated on or before day 5 of a
cycle) or delayed (initiated after day 5 of a cycle) [19,21].
The analysis sample of the study only included cycles in
which G-CSF was used prophylactically. We used G-CSF
initiation during days 1–5 after the start of the cycle to
identify prophylaxis for two reasons: most chemotherapy
regimens are administered over a 1- to 3-day period, and
G-CSF prophylaxis is recommended to be initiatedwithin 24 to 72 hours after chemotherapy (ie, generally
by the end of cycle day 5); febrile neutropenia rarely
occurs within the first 5 days of a cycle, and thus G-CSF
use during this period would almost certainly constitute
prophylaxis rather than treatment for febrile neutropenia.
Cycles associated with delayed G-CSF use were excluded
from the analysis. Neutropenia-related hospitalization
and other healthcare encounters were defined with both
a “narrow” criterion for claims with neutropenia (288),
and with a “broad” criterion for claims with neutropenia
or fever of unknown origin (ICD-9: 780.6) or infection
(codes are listed in the Additional file 1). The primary
study endpoints were whether all-cause hospitalization
and neutropenia-related hospitalization (ie, hospitaliza-
tions for which there were neutropenia codes as defined
above) occurred within a chemotherapy cycle associated
with filgrastim or pegfilgrastim prophylaxis.
Utilization and cost data
Healthcare utilization and costs were calculated for each
cycle. Total all-cause costs were calculated as the costs
associated with all medical and pharmacy claims during
the cycle. Physician fees, chemotherapy costs, and G-CSF
costs were all included in the total all-cause cost measure.
Additionally, all-cause utilization and costs were calcu-
lated separately for emergency room (ER) visits, hospitali-
zations, and ambulatory care visits (outpatient hospital
and office-based visits). Hospitalization length of stay was
another examined utilization outcome. Drugs delivered as
part of medical benefits (eg, administered chemotherapy)
were included in the costs for each setting of care: ER,
hospital inpatient, and ambulatory care. Retail pharmacy
costs were calculated as the cost for all prescription
claims and considered as a component of total costs in
the ambulatory care setting. Neutropenia-related utilization
and costs were calculated from claims associated with neu-
tropenia. The costs represented the reimbursed amount
paid by the patient and insurer. Only direct costs for ser-
vices covered under the patient’s insurance benefit were
included in this study.
Statistical analyses
Descriptive statistics regarding patient characteristics
and cycle characteristics (in terms of chemotherapy
agents received and G-CSF administration patterns) were
calculated for filgrastim and pegfilgrastim separately.
Additionally, descriptive statistics were calculated for
healthcare utilization, costs, and length of hospital stay
during cycles with filgrastim or pegfilgrastim prophylaxis.
Statistical tests were used based on the distribution of
the data (eg, t-test for continuous variables and chi-
squared test for categorical data). Odds ratios (OR) and
95% confidence intervals (CI) for hospitalization in cycles
with pegfilgrastim prophylaxis compared to cycles with




Patients with continuous enrollment (index date minus 365
to index date)
72,978 48.3
Patients with index cancer (BC, CRC, LC, NHL, Ovarian) 18,186 24.9
Patients meeting criteria for eligible course 10,219 56.2
Patients without stem cell transplant 10,207 99.9
Patients without use of nursing facility 9,989 97.9
Patients with G-CSF use during at least one cycle 4,684 46.9
Patients without radiation on index date 4,531 96.7
Patients without more than one primary cancer site† 3,958 87.4
Patients with prophylactic G-CSF use in at least one cycle 3,535 89.3
Patients with prophylactic pegfilgrastim use 3,372 95.4
Patients with prophylactic filgrastim use 163 4.6
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mating equation (GEE) models. The GEE models
included up to the ninth chemotherapy cycle for each pa-
tient. This restriction was included because failure to do
so resulted in GEE model estimation that failed to con-
verge. A binomial distribution with log link was specified
for all GEEs, and the models were fit using an exchange-
able correlation structure. To control for possible con-
founding between G-CSF agent and outcomes, ORs were
adjusted for patient age and sex, cancer type, myelotoxi-
city of chemotherapy, chronic comorbidities (as assessed
with the Quan-Charlson comorbidity index [27]), and
history of anemia in the 120 days prior to each cycle. A
conventional alpha of 0.05 was used without adjustment
for multiplicity. All statistical analyses were performed
with SAS version 9.1 (SAS Institute Inc., Cary, NC) and
Stata version 10 SE (StataCorp, College Station, TX).Patient-cycles with G-CSF prophylaxis in 3,535 patients 12,056
Pegfilgrastim 11,683 96.9
Filgrastim 373 3.1





BC – breast cancer, CRC – colorectal cancer, LC – lung cancer, and NHL – non-
Hodgkin’s lymphoma.
* Patients with any evidence of chemotherapy from January 1, 2005 to
February 28, 2009 (index date set to first administration) and no
chemotherapy from index date −365 to index date −1.
† Primary cancers defined as: 140.xx – 172.xx, 174.xx – 195.xx and 199.xx – 208.xx.Sensitivity analysis
Sensitivity analyses were performed to determine
whether other factors could affect the results. First, we
examined the impact of excluding filgrastim cycles with
a shorter duration (ie, less than 4 days of filgrastim
prophylaxis) of filgrastim prophylaxis. Second, as the ex-
clusion of patients with evidence of more than one pri-
mary cancer could inappropriately exclude patients with
only one primary cancer (in case metastases were in-
appropriately coded as additional primary cancers), that
criterion was removed.Results
Patient characteristics
The initial population from the claims database con-
tained 151,118 patients receiving chemotherapy. After
applying the inclusion and exclusion criteria, the eli-
gible population included 3,535 patients with breast
cancer, lung cancer, NHL, ovarian cancer, or colorectal
cancer receiving G-CSF prophylaxis. These patients
represented 12,056 cycles during which G-CSF was
delivered prophylactically, including 373 filgrastim
cycles and 11,683 pegfilgrastim cycles (Table 1). Base-
line demographics indicated that most patients were
female with a mean age of 55, with half of the pati-
ents from the Southern region of the United States
(Table 2). About half of the patients had breast cancer,
with the next most frequent cancers being lung cancer
(18%) and NHL (17%). Among all patient-cycles in the
sample, about 32% were associated with a history of
anemia in the 120 days prior to the start of each cycle.
Filgrastim was used for a mean (SD) of 4.8 (3.3) injec-
tions per cycle compared to 1.0 (0.2) injections per
cycle with pegfilgrastim, which was consistent with
pegfilgrastim’s once-per-cycle indication.Risk of hospitalization
Hospitalization data for a narrow definition of neutro-
penia, a broad definition of neutropenia, and all causes
were calculated and are described herein. The incidence
of neutropenia-related hospitalization (narrow defin-
ition) per cycle was 1.3% (95% CI: 0.4%–3.1%) with
prophylactic filgrastim and 0.6% (95% CI: 0.5%–0.7%)
with prophylactic pegfilgrastim (P = 0.063); neutropenia-
related hospitalization (broad definition) per cycle also
occurred at a higher incidence with prophylactic filgras-
tim than with prophylactic pegfilgrastim (6.7% [95% CI:
4.4%–9.7%] vs. 2.4% [95% CI: 2.1%–2.7%], P < 0.001); a
higher incidence with prophylactic filgrastim than with
prophylactic pegfilgrastim in all-cause hospitalizations
per cycle was observed as well (10.2% [95% CI: 7.3%–
13.7%] vs. 5.0% [95% CI: 4.6%–5.4%], P < 0.001).
When compared with cycles in which filgrastim was
prophylactically used, cycles in which prophylactic peg-
filgrastim was used were associated with a reduction in
the risk of all-cause hospitalizations (odds ratio [OR] of
0.50, 95% CI: 0.35–0.72, P < 0.001) and neutropenia-
related hospitalization (narrow definition: OR: 0.43, 95%
CI: 0.16–1.13, P = 0.087; broad definition: OR: 0.38, 95%
Table 2 Patient characteristics
Patient-level Characteristics Total (N = 3,535) Filgrastim (N = 163) Pegfilgrastim (N = 3,372) P-value
Age, mean (SD) 55.2 (10.8) 57.5 (12.6) 55.1 (10.7) 0.018
Female, n (%) 2,788 (78.9) 119 (73.0) 2,669 (79.2) 0.060
Geographic region, n (%)
Northeast 248 (7.0) 26 (16.0) 222 (6.6) <0.001
Midwest 970 (27.4) 38 (23.3) 932 (27.6) 0.227
South 1,778 (50.3) 79 (48.5) 1,699 (50.4) 0.632
West 539 (15.3) 20 (12.3) 519 (15.4) 0.279
Tumor type, n (%)
Breast cancer 2,054(58.1) 84 (51.5) 1,970 (58.4) 0.082
Colorectal cancer 46 (1.3) 7 (4.3) 39 (1.2) <0.001
Lung cancer 634 (17.9) 30 (18.4) 604 (17.9) 0.873
Non-Hodgkin’s lymphoma 594 (16.8) 33 (20.3) 561 (16.6) 0.229
Ovarian cancer 207 (5.9) 9 (5.5) 198 (5.9) 0.852
Baseline Quan-Charlson comorbidity score, mean (SD)*† 4.5 (2.4) 4.4 (2.5) 4.5 (2.4) 0.520
Score of 2, n (%) 1,131 (32.0) 57 (35.0) 1,074 (31.9) 0.404
Score of 3–6, n (%) 1,590 (45.0) 61 (37.4) 1,529 (45.3) 0.047
Score of≥ 7, n (%) 805 (22.8) 44 (27.0) 761 (22.6) 0.188
History of anemia‡§ 3,858 (32.0) 135 (36.2) 3,723 (31.9) 0.078
Count of myelosuppressive chemotherapy agents,
mean (SD) for cycles§**
2.13 (0.6) 1.96 (0.6) 2.14 (0.6) <0.001
Use duration, mean (SD)†† - 4.8 (3.3) ‡‡ -
1 day, % - 19.9 - -
2 days, % - 9.9 - -
3 days, % - 14.0 - -
4–6days, % - 23.9 - -
≥ 7 days, % - 32.3 - -
* Baseline is the 1-year period preceding the index date (start of chemotherapy course).
† Nine patients (0.3%) had a score of 0 (7 patients) or 1 (2 patients).
‡ Anemia occurring in the 120 days prior to the start of each cycle.
§ Cycle-level data: 12,056 total cycles of which 373 were filgrastim and 11,683 were pegfilgrastim.
** Data by cycle, not by patient, as myelosuppressive characteristics were determined at the cycle level.
†† Calculated from cycles in which filgrastim or pegfilgrastim were found on medical claims. Cycles with pharmacy claims for either were not included, as the precise date
for the administration of filgrastim or pegfilgrastim could not be determined. These criteria resulted in 322 filgrastim cycles and 11,510 pegfilgrastim cycles.
‡‡ For pegfilgrastim, there was a mean (SD) of 1.0 (0.15) claims per cycle.
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disease, and treatment characteristics in GEE models
(Table 3, Figure 1).
Sensitivity analyses were conducted to examine the
possible effects of length of filgrastim prophylaxis and
the presence of more than one primary cancer.
Hospitalization risk for cycles in which filgrastim was
used for 4 or more days was examined. The OR for the
comparison between filgrastim and pegfilgrastim did not
change appreciably from those observed in the primary
analysis (Figure 1). Similar findings were observed when
patients with more than one primary cancer were
included in the analyses (data not shown).
Healthcare utilization and costs
Healthcare resource utilization and costs on a per-cycle
basis were examined for neutropenia-related causes(with both the broad and narrow criteria for neutro-
penia) and all causes (Table 4). Because similar findings
were observed for both definitions of neutropenia, we
only described results based on the more restrictive def-
inition here.
For neutropenia-related utilization per cycle for all
cycles (including cycles without neutropenia-related
utilization), there were more ambulatory visits (2.1 vs.
0.36 per cycle, P < 0.001) and hospitalizations (0.02 vs.
0.01 per cycle, P = 0.146) with filgrastim than with peg-
filgrastim (mean ER visits were 0 for both groups). In
the subset of filgrastim cycles in which neutropenia-
related hospitalization occurred (5 cycles, 1.34% among
all 373 filgrastim cycles), an average of 1.4 neutropenia-
related hospitalizations occurred per cycle, with mean
length of stay of 12.6 days. In the subset of pegfilgras-
tim cycles in which neutropenia-related hospitalization
Table 3 Adjusted odds ratios for risk of hospitalization by G-CSF
Variable Neutropenia-Related All-Cause
Narrow Definition Broad Definition
OR (95% CI) OR (95% CI) OR (95% CI)
Prophylactic pegfilgrastim (vs. prophylactic filgrastim) 0.43 (0.16–1.13) 0.38 (0.24–0.59) 0.50 (0.35–0.72)
Age 1.01 (0.99–1.03) 1.00 (0.99–1.01) 1.00 (1.00–1.01)
Gender male 0.79 (0.39–1.59) 1.40 (1.03–1.90) 0.94 (0.94–1.18)
Baseline Quan-Charlson comorbidity score 1.02 (0.96–1.14) 1.09 (1.04–1.15) 1.07 (1.03–1.11)
Prior anemia 0.95 (0.57–1.58) 1.30 (1.02–1.66) 1.34 (1.13–1.60)
Breast cancer* 0.28 (0.14–0.56) 0.44 (0.32–0.61) 0.47 (0.38–0.59)
Lung cancer* 0.22 (0.07–0.64) 0.54 (0.37–0.77) 0.84 (0.65–1.08)
Number of myelosuppressive chemotherapy agents† 2.28 (1.33–3.89) 0.86 (0.68–1.07) 0.95 (0.81–1.12)
All odds ratios (OR) are adjusted for the other variables listed.
* Compared to NHL, ovarian cancer, and colorectal cancer.
† Myelosuppressive chemotherapy agent was defined as one of the following agents: bendamustine, busulfan, capecitabine, carboplatin, carmustine, chlorambucil,
cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil,
hydroxyurea, idarubicin, ifosfamide, irinotecan, ixabepilone, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin,
paclitaxel, pemetrexed disodium, procarbazine, temozolomide, teniposide, thiotepa, or topotecan.
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tim cycles), an average of 1.0 neutropenia-related
hospitalization occurred per cycle, lasting a mean of
7.0 days each. Among all filgrastim cycles, 39.7% were
associated with at least one neutropenia-related ambu-
latory visit; the corresponding percentage among all
pegfilgrastim cycles was 28.0%. During the subset of
cycles in which these neutropenia-related ambulatory
visits occurred, the mean number of neutropenia-related
visits was 5.3 for filgrastim cycles and 1.3 for pegfilgras-
tim cycles. All-cause resource utilization showed similar
trends as that indicated for neutropenia-related results,
and specific all-cause healthcare utilization results can be
seen in Table 4.Figure 1 Odds ratios for neutropenia-related and all-cause hospitaliza
filgrastim. Odds ratios (ORs) and 95% confidence intervals (95% CI) for hos
adjusted for patient, cancer, and chemotherapy characteristics. The primary
The subgroup analysis only included those cycles in which patients receive
under “Sensitivity Analyses”).Per-cycle costs were also examined by setting of care:
ambulatory care, ER, and inpatient hospitalizations
(Figure 2). Mean neutropenia-related per-cycle costs
for all cycles (including cycles without neutropenia-
related utilization) were greater for filgrastim than for
pegfilgrastim ($1,601 vs. $1,150, P = 0.022), with the
difference being driven by the greater costs of ambula-
tory care ($1,421 vs. $1,054, P = 0.004). The mean
neutropenia-related hospitalization cost per cycle (includ-
ing cycles without neutropenia-related hospitalization
events) was also numerically greater for filgrastim than for
pegfilgrastim ($180 vs. $88, P = 0.523). For the subset of
cycles in which neutropenia-related hospitalizations oc-
curred (as opposed to all cycles), the mean neutropenia-tion regarding prophylactic pegfilgrastim versus prophylactic
pitalization are shown with pegfilgrastim versus filgrastim prophylaxis,
analysis included all cycles in which G-CSF was used prophylactically.
d 4 or more days of filgrastim (as described in the Methods section
Table 4 All-cause and neutropenia-related utilization by cycle
Total (N = 12,056) Filgrastim (N = 373) Pegfilgrastim (N = 11,683)
All-cause Hospitalizations n (%)* 620 (5.1) 38 (10.2) 582 (5.0)
Mean ± SD† 0.06 ± 0.26 0.14 ± 0.46 0.05 ± 0.25
Ambulatory visits n (%)* 12,051 (100) 373 (100) 11,678 (100)
Mean ± SD† 5.5 ± 3.7 9.5 ± 5.9 5.4 ± 3.5
Emergency room visits n (%)* 943 (7.8) 27 (7.2) 916 (7.8)
Mean ± SD† 0.11 ± 0.46 0.09 ± 0.32 0.11 ± 0.46
Neutropenia- related Hospitalizations n (%)* 73 (0.61) 5 (1.34) 68 (0.58)
Mean ± SD† 0.01 ± 0.08 0.02 ± 0.17 0.01 ± 0.08
Ambulatory visits n (%)* 3,422 (28.4) 148 (39.7) 3,274 (28.0)
Mean ± SD† 0.42 ± 0.93 2.1 ± 3.3 0.36 ± 0.68
Emergency room visits n (%)* 32 (0.27) 1 (0.27) 31 (0.27)
Mean ± SD† 0.00 ± 0.05 0.00 ± 0.05 0.00 ± 0.05
* Number of cycles with the event and percentage of those cycles among all cycles.
† Mean and standard deviation of the number of events per cycle.
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appeared to be statistically insignificant from the $15,069
cost per pegfilgrastim cycle (P = 0.892). In the subset of
cycles in which neutropenia-related ambulatory visits oc-
curred, mean neutropenia-related ambulatory care costs
per cycle with filgrastim were also similar to those for peg-
filgrastim ($2,023 vs. $2,159, P = 0.413).
The combined mean costs per cycle due to all cause
for all cycles were fairly similar for the two G-CSF mole-
















































Figure 2 Costs per cycle: All-cause and neutropenia-related. Healthcar
used prophylactically, were calculated on a per-cycle basis to provide total
emergency room, and hospitalizations. The costs were direct costs for serv
reimbursed amount paid by the patient and insurer.pegfilgrastim (P = 0.756). Compared to pegfilgrastim,
there were lower ambulatory care costs for filgrastim
($7,788 vs. $8,933, P = 0.004) and greater hospitalization
costs for filgrastim ($1,769 vs. $815, P = 0.054).
Discussion
In this retrospective United States claims analysis, use
of prophylactic pegfilgrastim was associated with a
decreased risk of neutropenia-related hospitalization














































e resource costs, for cycles in which pegfilgrastim and filgrastim were
costs as well as subgroup costs by setting of care: ambulatory care,
ices covered under patients’ insurance benefits and represented the
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http://www.biomedcentral.com/1471-2407/13/11definition: OR = 0.38, 95% CI: 0.24–0.59) and all-cause
hospitalization (OR = 0.50, 95% CI: 0.35–0.72) when
compared to that seen with the use of prophylactic fil-
grastim. Patients who received filgrastim prophylaxis in
this study had a mean 4.8 days of prophylaxis, which is
much shorter than the duration which has been demon-
strated to be non-inferior to pegfilgrastim prophylaxis in
clinical trials [14-18]. These results are consistent with
previous findings that hospitalization risk was more sig-
nificantly reduced by pegfilgrastim prophylaxis than by
filgrastim prophylaxis in clinical practice [20-23]. Key
findings regarding utilization included an increase in
neutropenia-related ambulatory visits and hospitalizations
with filgrastim prophylaxis compared to pegfilgrastim
prophylaxis. In addition, mean per-cycle neutropenia-
related costs were greater with filgrastim prophylaxis than
with pegfilgrastim prophylaxis.
In a previous study that used a large managed care
claims database in the United States, Weycker et al. per-
formed a retrospective cohort analysis of cancer patients
who received filgrastim or pegfilgrastim during their first
course of chemotherapy (2003–2005) [21]. Both all-
cause (OR = 0.73, 95% CI: 0.59–0.91) and neutropenia-
related (narrow definition: OR = 0.64, 95% CI: 0.41–0.99;
broad definition: OR = 0.69, 95% CI: 0.52–0.92)
hospitalization risk was lower with pegfilgrastim prophy-
laxis compared to filgrastim prophylaxis. Two subse-
quent claims studies reported similar results [22,23].
The consistent finding that filgrastim prophylaxis is
associated with higher hospital risks than pegfilgrastim
prophylaxis may be related to the less than optimal use
of filgrastim in clinical practice. Specifically, while in the
comparative clinical trials, filgrastim was given for an
average of 10–11 days [14-18]; in the clinic, filgrastim is
often given for far fewer days, resulting in suboptimal
prevention of neutropenia and thus greater rates of
hospitalization for neutropenic complications [19-23].
One distinct aspect of this study is that compara-
tive filgrastim and pegfilgrastim costs and resource
utilization data were reported, including details such
as the number of hospitalizations, ambulatory and
ER visits, and per-cycle costs. Comparative studies
assessing cost and resource utilization of filgrastim and
pegfilgrastim in the United States are limited. A retro-
spective single-time-point survey conducted by Fortner
et al. assessed the human resource costs required for
administering filgrastim or pegfilgrastim [28]. They
concluded that a single administration with filgrastim
or pegfilgrastim had equivalent human resource costs,
but because of the greater number of visits required
with filgrastim, the total time and human resource cost
with filgrastim (14.8 hours and $364.66) in a 21-day
chemotherapy cycle were more than those with pegfil-
grastim (2.4 hours and $57.30).In this study utilizing a large claims database, all-
cause costs were roughly equivalent for filgrastim and
pegfilgrastim on a per-cycle basis, with more spent on
hospitalizations with filgrastim and more spent on am-
bulatory care with pegfilgrastim. It is interesting to
note that although pegfilgrastim cycles had greater
costs for ambulatory care, there were proportionally
more ambulatory visits for filgrastim cycles. The
increased all-cause per-cycle cost of pegfilgrastim am-
bulatory care may reflect the greater drug costs of
pegfilgrastim compared to filgrastim, especially when
fewer than the recommended number of filgrastim
doses were administered. Neutropenia-related costs
were greater for filgrastim than pegfilgrastim because
of the greater costs of both inpatient and ambulatory
care during filgrastim cycles. Overall, these data sug-
gest that the greater drug costs with pegfilgrastim are
offset by decreased hospitalization costs.
There are several sources of bias and limitations in-
herent in the study design that could influence inter-
pretation of these results. As this was a database of a
large employment-sponsored managed care population,
patients would most likely be in the 18–64 year age
range. Thus, the effects of G-CSF on outcomes in the
population of patients aged 65 years or above were not
fully captured. Additionally, the data are dependent on
the accuracy of claims coding and hence contain any
errors or omissions that occurred during that coding.
By using the broad criteria for neutropenia, as well
as all-cause utilization, we were able to more accur-
ately provide upper limits for our estimates. It should
be noted that this study compared risk between
treatment cohorts. The potential under-coding and
mistakes in coding of febrile neutropenia are unlikely
to be associated with G-CSF selection and thus do
not affect the estimates of interest (ie, ORs). Sample
size is another issue that affects the statistical power
of our estimates, as there were fewer than 400 cycles
with prophylactic filgrastim use. Another source of
bias is the assumption that G-CSF administration by
day 5 of a cycle represents prophylaxis rather than
treatment. Although this definition has been used in
other studies [19,21], its validity has not yet been
confirmed in the literature. Thus, it is uncertain
whether earlier or later onset of administration may
represent prophylaxis or treatment in a clinical set-
ting. Likewise, our categorization of certain cycles as
containing highly myelosuppressive chemotherapy
based on the presence of individual agents used in
that cycle may not adequately capture the various
factors that affect the myelosuppressive effects of a
chemotherapy regimen, such as combination chemo-
therapy and doses of specific agents. Furthermore,
potential differences across health plans covered in
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of costs between filgrastim and pegfilgrastim cycles.
It is unclear whether this study adequately captured
the various known patient, disease, and treatment char-
acteristics that are risk factors for developing febrile
neutropenia [6,12]. The claims database contained sev-
eral of these, such as age, sex, comorbidities, recent his-
tory of anemia, history of radiation, tumor type, and
number of myelosuppressive agents. To reduce the effect
of possible selection bias, data were adjusted for those
covariates in the GEE model. However, the claims data-
base did not include other potential predictors of febrile
neutropenia, such as treatment intent, disease stage,
chemotherapy dose, previous febrile neutropenia events,
laboratory values, and concomitant medications. Some
of these factors could influence selection of G-CSF as ei-
ther filgrastim or pegfilgrastim. Thus the study results
may still be confounded by possible differences in those
unobserved characteristics between filgrastim and pegfil-
grastim groups.
The use of per-cycle analyses for utilization and costs
has the disadvantage of not capturing costs associated
with cycles in which G-CSF was not administered. How-
ever, per-patient analyses would not allow us to tempor-
ally associate use of either G-CSF with utilization. For
instance, in a per-patient analysis, a patient hospitalized
in cycle 1 who subsequently received G-CSF in cycle 2
would have those two events associated, when clearly
the hospitalization was independent of any effects from
G-CSF. Another disadvantage of per-patient analyses is
that while on average, each patient who received filgras-
tim received it for a mean of 2.3 cycles, while each pa-
tient who received pegfilgrastim received it for a mean
of 3.5 cycles. The accompanying drug costs would make
it difficult to discern any possible effect of either medica-
tion on all-cause medical costs.
In conclusion, the results of this claims analysis in-
dicate that prophylactic use of filgrastim as compared
with pegfilgrastim is associated with an increased
risk of hospitalization from all causes as well as
neutropenia-related causes. Results from this analysis
and others indicate that other factors influence the
risk of hospitalization, including comorbidities, his-
tory of anemia, age, and presence of metastatic dis-
ease [2,6,11,12,29]. Future studies that explore the
role of these characteristics will help further clarify
the various factors that lead to febrile neutropenia
and associated complications.
Conclusions
This retrospective comparative effectiveness study
used claims data to examine prophylactic use of fil-
grastim and pegfilgrastim in cancer patients receiving
chemotherapy. The key finding of the study is thatpegfilgrastim prophylaxis was associated with a reduced
risk of hospitalization due to neutropenia or all-cause.
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